ArriVent Biopharma
ArriVent BioPharma (NASDAQ: AVBP) is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines for the treatment of cancer. Its lead candidate is firmonertinib, an EGFR inhibitor being studied across non-small cell lung cancer indications, and its pipeline includes next-generation antibody drug conjugates such as ARR-002. The company operates by identifying novel oncology programs, in-licensing drug candidates through partnerships, and designing regulatory-compliant clinical development strategies. It was surfaced as a portfolio company of HongShan and added to the API Evangelist network; as a traditional pharmaceutical developer it publishes no public API, developer portal, or technical integration surface.
Index entry only — little beyond a description and a link, and nothing machine-readable enough for an agent to act on without a human reading the site first.
API Evangelist profiles ArriVent Biopharma the way a machine reads it — 1 machine-readable artifact, pulled from the provider's own public surface and indexed so a developer, an analyst, or an AI agent can evaluate it against every other provider on the network.
Every provider in the network is reduced to the same set of machine-readable artifacts — OpenAPI contracts, event specifications, GraphQL schemas, runnable collections, pricing and rate-limit signals, security posture, OAuth scopes, and the agent surfaces (MCP servers and skills) that let software drive the API on its own. We profile them because the interface is the part of a company you can actually inspect: it is a truer signal of what a provider does than any marketing page. From those artifacts we compute the Kin Score — ArriVent Biopharma scores 7.7/100 (minimal), with a separate agent-readiness read of 0/100 (human only). The full breakdown is below, followed by every artifact we hold — each card links through to its machine-readable definition on apis.io.
Kin Score
This is the API Evangelist rating — a single, repeatable read computed from the artifacts on this page. Green fill is points earned; the red track is points possible, so every bar shows earned-versus-possible at a glance.
Kin Score
How this is scored →scored 2026-07-27 · rubric v0.5
How we profile ArriVent Biopharma
Each block below is one kind of artifact we hold for ArriVent Biopharma. For each we say what it is and why it earns a place in the profile, then list every one we've indexed — capped at two rows, scroll within the panel for the rest.
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals — the evidence that a provider takes security seriously enough to document it. We profile it because you can't govern what you can't see.
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Every other property we hold for ArriVent Biopharma — documentation, portals, status pages, policies, and corporate surface — grouped by the job it does, following the integrator's arc from getting started to running in production.
Access & Security 1
Authentication, authorization, and security posture
Company 1
The organization behind the API
← All providers · Data indexed from github.com/api-evangelist/arrivent-biopharma · machine-readable index on apis.io